BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12658892)

  • 1. HER-2 inhibitors: clinical results.
    Crinò L; Franceschi E; Scopece L
    Suppl Tumori; 2002; 1(6):S3-4. PubMed ID: 12658892
    [No Abstract]   [Full Text] [Related]  

  • 2. Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma.
    Ropero S; Menéndez JA; Vázquez-Martín A; Montero S; Cortés-Funes H; Colomer R
    Breast Cancer Res Treat; 2004 Jul; 86(2):125-37. PubMed ID: 15319565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [ERBB2/HER2: from molecular to clinical oncology].
    Khanson KP; Imianitov EN
    Vopr Onkol; 2002; 48(2):137-45. PubMed ID: 12227060
    [No Abstract]   [Full Text] [Related]  

  • 4. ErbB/HER receptor family in breast cancer--the more we search the more we learn.
    Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
    Ann Oncol; 2008 May; 19(5):1020-1. PubMed ID: 18356136
    [No Abstract]   [Full Text] [Related]  

  • 5. New molecule-targeting therapy with herceptin (trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody.
    Sakamoto G; Mitsuyama S
    Breast Cancer; 2000; 7(4):350-7. PubMed ID: 11114864
    [No Abstract]   [Full Text] [Related]  

  • 6. Tamoxifen: Dr. Jekyll and Mr. Hyde?
    Hayes DF
    J Natl Cancer Inst; 2004 Jun; 96(12):895-7. PubMed ID: 15199102
    [No Abstract]   [Full Text] [Related]  

  • 7. Current status of antibody therapy for breast cancer.
    Toi M; Takada M; Bando H; Toyama K; Yamashiro H; Horiguchi S; Saji S
    Breast Cancer; 2004; 11(1):10-4. PubMed ID: 14718785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth and molecular interactions between tamoxifen and trastuzumab.
    Vázquez-Martín A; Colomer R; Ropero S; Abel Menéndez J; Argiris A; Wang CX; Koay DC; Digiovanna MP
    Clin Cancer Res; 2005 May; 11(9):3597; author reply 3597-9. PubMed ID: 15867265
    [No Abstract]   [Full Text] [Related]  

  • 9. Her2-neu: a target in lung cancer?
    Andre F; Le Chevalier T; Soria JC
    Ann Oncol; 2004 Jan; 15(1):3-4. PubMed ID: 14679110
    [No Abstract]   [Full Text] [Related]  

  • 10. HER2 as a cancer stem-cell target.
    Roesler R; Cornelio DB; Abujamra AL; Schwartsmann G
    Lancet Oncol; 2010 Mar; 11(3):225-6. PubMed ID: 20202610
    [No Abstract]   [Full Text] [Related]  

  • 11. Her2 and trastuzumab in breast cancer.
    Horton J
    Cancer Control; 2001; 8(1):103-10. PubMed ID: 11176040
    [No Abstract]   [Full Text] [Related]  

  • 12. The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.
    Slamon DJ
    Oncologist; 2004; 9 Suppl 3():1-3. PubMed ID: 15163840
    [No Abstract]   [Full Text] [Related]  

  • 13. Update on HER-kinase-directed therapy in prostate cancer.
    Gross ME; Jo S; Agus DB
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The distinctive nature of HER2-positive breast cancers.
    Burstein HJ
    N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of ErbB inhibitors in trastuzumab resistance.
    Miller KD
    Oncologist; 2004; 9 Suppl 3():16-9. PubMed ID: 15163843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of estrogen responsiveness by blocking the HER-2/neu pathway.
    Witters L; Engle L; Lipton A
    Oncol Rep; 2002; 9(6):1163-6. PubMed ID: 12375012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Her2 positive breast cancer: practices].
    Campone M; Berton-Rigaud D; Bourbouloux E; Sophie S; Zanetti A; Frenel JS
    Bull Cancer; 2011 Feb; 98(2):154-63. PubMed ID: 21591301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
    Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A
    Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625
    [No Abstract]   [Full Text] [Related]  

  • 19. Trastuzumab.
    Perez EA; Palmieri FM; Brock SM
    Cancer Treat Res; 2009; 151():181-96. PubMed ID: 19593513
    [No Abstract]   [Full Text] [Related]  

  • 20. Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response?
    Thor A
    J Natl Cancer Inst; 2001 Aug; 93(15):1120-1. PubMed ID: 11481375
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.